| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive Chair & Principal Officer | Executive Chair & Principal Officer | See Remarks +5 more
3 companies
Garo H Armen is Director at INKT and has filed Form 4s across 3 companies. From September 2015 to August 2026, the filings on record show 14 open-market purchases and 3 sales. Garo H Armen's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $22.7M at current prices.
Historically, Garo H Armen's trades have earned a middling insider score of 56/100 across 6 rated trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +8.2%.
The biggest single holding is INKT (~$20.1M) as Director.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 13, 2021 | AGEN Agenus Inc | Chairman and CEO | Sale+OE | 82,107 | $6.50 | $533,695.50 | -9.6% | -49.4% | -60.8% | |
| Apr 12, 2017 | AGEN Agenus Inc | Chairman & CEO | Buy | 100,000 | $3.35 | $334,519.79 | +7.6% | - | - | |
| Jun 17, 2016 | PTIX Protagenic Therapeutics, Inc.\new | See Remarks | Buy | 60,211 | $1.25 | $75,263.75 | +1.4% | - | - | |
| May 9, 2016 | AGEN Agenus Inc | Chairman & CEO | Buy | 100,000 | $3.18 | $317,895.00 | +7.7% | - | - | |
| Mar 7, 2016 | AGEN Agenus Inc | Chairman & CEO | Buy | 200,000 | $4.03 | $805,600.00 | +19.0% | - | - | |
| Dec 29, 2015 | AGEN Agenus Inc | Chairman & CEO | Sell | 219,576 | $4.59 | $1,007,877.33 | -15.3% | - | - | |
| Sep 25, 2015 | AGEN Agenus Inc | Chairman & CEO | Buy | 100,000 | $5.03 | $503,000.00 | +7.6% | - | - |